Login to Your Account

CEO: 'Unexpected Lightning Bolt'

Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls

By Jennifer Boggs

Wednesday, March 19, 2008
The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription